Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection

doi:10.19803/j.1672-8629.2022.02.04

Abstract

Abstract: Objective To make an in-depth study on the clinical characteristics of Shengmai Injection (SMI) in the treatment of heart failure and the patterns of combined medications based on the real world data from the hospital information system (HIS). Methods R software was used to analyze the data on 4 832 patients with heart failure in HIS databases from January 1, 2002 to December 31, 2016. Results There were 2 273 male patients and 2 499 female ones, but the data on gender was missing for 60 patients. The age of the patients averaged (72.57±13.45) years old and the length of hospital stay averaged (22.18±19.28) days. The main route of administration of SMI was intravenous drip (3 915 cases, accounting for 81.02%). The average single dose was (57.16±20.16) mL, and the average course of treatment was (4.76±6.16) days. The most commonly-used drug combinations included spironolactone+furosemide, and acetylsalicylic acid+spironolactone+furosemide. Conclusion This real world study of combined medications for heart failure has shed light on the basic clinical characteristics of patients with heart failure in the real world and the medication characteristics of SMI and provided reference for clinicians.

Key words: real world study, Shengmai injection, heart failure, hospital information system, clinical characteristics

CLC Number:

R994.11

SUN Chunquan, XIE Yanming, HOU Hengyue. Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.

References

[1] ZHENG BH, ZHAN SY, ZHOU HY, et al.Research progress on composition, preclinical pharmacokinetics and pharmacodynamics of Shengmai injection[J]. Chinese Herbal Medicine(中草药), 2020, 51(20): 5360-5371.
[2] Chinese guidelines for diagnosis and treatment of heartfailure 2018[J]. Journal of Chinese Heart Failure and Cardiomyopathy(中华心力衰竭和心肌病杂志), 2018, 2(4): 196-225.
[3] ZHUANG Y, XIE BT, WENG SX, et al.Discussion on the design method of his "real world" integrated data warehouse for post marketing reevaluation of traditional Chinese medicine[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2011, 36(20): 2880.
[4] CHEN Z, WU JJ.Research on medical data mining based on association rules[J]. Statistics and Decision(统计与决策), 2020, 36(6): 174-177.
[5] GU DF, HUANG GY, HE J, et al.Epidemiological investigation and prevalence of heart failure in China[J]. Journal of Chinese Cardiology(中华心血管病杂志), 2003, 31(1): 3-6.
[6] WANG H, LI YY, Chai K, et al.Epidemiology and treatment status of hospitalized heart failure patients in China[J]. Journal of Chinese Cardiology(中华心血管病杂志), 2019, 47(11): 865-874.
[7] ZHANG Y, ZHANG J, BUTLER J, et al.Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (ChinaHF) region[J]. J Card Fail, 2017, 23(12): 868-875.
[8] ZHANG J, GAN TY.Cardiovascular emergency treatment (5) diagnosis and differential diagnosis of dyspnea (continued 4)[J]. Journal of Chinese Circulation(中国循环杂志), 2014, 29(3): 164-166.
[9] WANG XJ.Adverse reactions and clinical rational use of traditional Chinese medicine injection[J]. Systems Medicine(系统医学), 2020, 5(19): 155-157.
[10] ZHANG W, ZHANG L, JI YN, et al.Analysis of irrational use of traditional Chinese medicine injections and prevention and treatment of adverse reactions[J]. Journal of World Traditional Chinese Medicine(世界中医药), 2019, 14(9): 2505-2508.
[11] CHEN KJ, WU ZG, ZHU MJ, et al.Expert consensus on diagnosis and treatment of chronic heart failure with integrated traditional Chinese and western medicine[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2016, 36(2): 133-141.
[12] MAO JY, ZHU MJ.Expert consensus on TCM diagnosis and treatment of chronic heart failure[J]. Journal of Traditional Chinese Medicine(中医杂志), 2014, 55(14): 1258-1260.
[13] ZHOU Q, QIN WZ, LIU SB, et al.Shengmai (a traditional Chinese herbal medicine) for heart failure[J]. Cochrane Database Syst Rev, 2014, 4: 1-77.
[14] FARIS RF, FLATHER M, PURCELL H, et al.Diuretics for heart failure[J]. Cochrane Database Syst Rev, 2012(2): 1-43.
[15] ROCHA R, WILLIAMS GH.Rationale for the use of aldosterone antagonists in congestive heart failure[J]. Drugs, 2002, 62(5): 723-731.
[16] DUNKMAN WB, JOHNSON GR, CARSON PE, et al.Incidence of thromboembolic events in congestive heart failure[J]. Circulation, 1993, 87(6): 94-101.
[17] ZHUANG XJ, GAO Y, GAO F, et al.Application of ambroxol hydrochloride oxygen mask atomization inhalation in elderly patients undergoing cardiac surgery and its effect on prevention of respiratory tract infection[J]. Journal of Chinese Nosocomial Infection(中华医院感染学杂志), 2016, 26(8): 1775-1777.
[18] Packer M, Coats AJ, Fowler MB, et al.Effect of carvedilol on survival in severe chronic heart failure[J]. N Engl J Med, 2001, 344(22): 1651-1658.
[19] State administration of traditional Chinese medicine. Notice on printing and distributing guiding principles for clinical application of chinese patent medicine[EB/OL].(2010-06-30)[2021-03-11]. http://www.satcm.gov.cn/yizhengsi/gongzuodongtai/2018-03-24/3071.html.